Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2632641 | 1.00 | DPP4 (0.40) | DPP4PHGDHMGLLOPRM1OPRD1 | |
| SCHEMBL6628519 | 1.00 | DPP4 (0.40) | DPP4PHGDHMGLLOPRM1OPRD1 | |
| SCHEMBL988738 | 0.98 | DPP4 (0.37) | DPP4PHGDHMGLLOPRM1OPRD1 | |
| SCHEMBL989317 | 0.98 | DPP4 (0.37) | DPP4PHGDHMGLLOPRM1OPRD1 | |
| SCHEMBL988739 | 0.98 | DPP4 (0.37) | DPP4PHGDHMGLLOPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL2875408 | 0.95 | OPRM1 (0.36) | DPP4PHGDHMGLLOPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL2875410 | 0.95 | OPRM1 (0.36) | DPP4PHGDHMGLLOPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL2876746 | 0.95 | OPRM1 (0.36) | DPP4PHGDHMGLLOPRM1OPRD1 | |
| SCHEMBL986628 | 0.93 | OPRM1 (0.34) | DPP4PHGDHMGLLOPRM1OPRD1 | |
| SCHEMBL897563 | 0.93 | OPRM1 (0.34) | DPP4PHGDHMGLLOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932350-B2 | Inhibitors of IRAK4 activity | MERCK SHARP & DOHME CORP. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170217981-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2017-08-03 | — | — | US | disclosed |
| US-9586899-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2017-03-07 | — | — | US | disclosed |
| US-8692002-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2014-04-08 | — | — | US | disclosed |
| EP-1666459-B1 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP (CA) | 2011-10-19 | — | — | EP | disclosed |
| EP-2298735-A1 | Aminocyclohexyl ether compounds and uses thereof | Cardiome Pharma Corp. (CA) | 2011-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217981-A1 | INHIBITORS OF IRAK4 ACTIVITY | IRAK4, IRAK1, IRAK2 | DPP4 84/4885PHGDH 4322/4885MGLL 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.